Researchers at the University of Kentucky’s Sanders-Brown Center on Aging (SBCoA) have recently screened the first participant of the AHEAD 3-45 study. This study is aimed at determining whether a medication known as BAN2401 can help prevent cognitive decline and worsening memory in individuals who may be at risk.
The AHEAD study is a Phase III clinical study that will be conducted in the United States, Japan, Canada, Australia, Singapore, and Europe. Participants are ages 55-80 with little to no cognitive impairment. While some of the participants have elevated amyloid levels in the brain and are at high risk for progressive cognitive impairment, other participants are below threshold for amyloid elevation but have high risk for further accumulation.
The study is a public-private partnership between the Alzheimer’s Clinical Trials Consortium (ACTC) and the pharmaceutical company Eisai. Dr. Paul Aisen from the University of Southern California and Drs. Reisa Sperling and Keith Johnson from Brigham and Women’s Hospital and Massachusetts General Hospital, Harvard Medical School are the three principal investigators leading the study.
“We are very excited about the AHEAD 3-45 project, as we are vigorously targeting amyloid at the earliest feasible stage of the disease spectrum, with treatment tailored to the amount of amyloid in the brain,” said Dr. Aisen.
“This is a really promising, large scale/multi-site effort, to see if we can make any breakthroughs in Alzheimer’s disease prevention,” said Shani Bardach, Ph.D., who is assistant professor of Gerontology and director of Clinical Trials Outreach and Recruitment at SBCoA.
By: Samuel Won, PharmD Candidate 2021